Uniqure (QURE) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Uniqure (NASDAQ:QURE) from a hold rating to a sell rating in a research report sent to investors on Friday.

According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “

A number of other equities analysts have also recently commented on the stock. B. Riley began coverage on shares of Uniqure in a research report on Monday, December 31st. They issued a buy rating and a $72.00 target price on the stock. Guggenheim began coverage on shares of Uniqure in a report on Monday, December 17th. They issued a buy rating and a $35.00 price target on the stock. HC Wainwright set a $60.00 price target on shares of Uniqure and gave the stock a buy rating in a report on Tuesday, December 4th. Chardan Capital reaffirmed a buy rating and set a $70.00 target price on shares of Uniqure in a research note on Monday, December 3rd. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $65.00 target price on shares of Uniqure in a research note on Thursday, November 15th. Two research analysts have rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $53.60.

Shares of NASDAQ:QURE opened at $29.88 on Friday. The firm has a market capitalization of $1.08 billion, a P/E ratio of -10.16 and a beta of 0.75. Uniqure has a 52 week low of $16.77 and a 52 week high of $43.23. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.56 and a current ratio of 7.56.

Uniqure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.03. The company had revenue of $3.15 million for the quarter, compared to analysts’ expectations of $3.37 million. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. As a group, equities analysts forecast that Uniqure will post -2.54 earnings per share for the current fiscal year.

In other news, insider Christian Klemt sold 5,739 shares of Uniqure stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $27.91, for a total transaction of $160,175.49. Following the sale, the insider now owns 40,000 shares of the company’s stock, valued at approximately $1,116,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip Astley-Sparke sold 5,000 shares of Uniqure stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $30.39, for a total transaction of $151,950.00. Following the transaction, the director now directly owns 23,252 shares of the company’s stock, valued at $706,628.28. The disclosure for this sale can be found here. Insiders own 1.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Bank of New York Mellon Corp raised its holdings in shares of Uniqure by 12.8% during the third quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock valued at $682,000 after purchasing an additional 2,129 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Uniqure by 24.2% during the third quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock valued at $649,000 after purchasing an additional 3,472 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Uniqure by 4.1% during the third quarter. Vanguard Group Inc. now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after purchasing an additional 3,992 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Uniqure by 4.1% during the third quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after purchasing an additional 3,992 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its holdings in shares of Uniqure by 9.4% during the third quarter. Allianz Asset Management GmbH now owns 54,332 shares of the biotechnology company’s stock valued at $1,977,000 after purchasing an additional 4,679 shares during the last quarter. 60.58% of the stock is owned by institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Story: How to calculate compound interest

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply